Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474464 | 1.00 | XDH (0.32) | XDHACHEALOX5MMESLC6A2 | |
| SCHEMBL2474924 | 0.93 | XDH (0.33) | XDHACHEALOX5SLC6A2SLC6A4 | |
| SCHEMBL2444538 | 0.93 | XDH (0.33) | XDHACHEALOX5SLC6A2SLC6A4 | |
| SCHEMBL2439186 | 0.84 | ALOX5 (0.36) | ACHEALOX5MMESLC6A2SLC6A4 | |
| SCHEMBL2439756 | 0.81 | ALOX5 (0.36) | ACHEALOX5MMESLC6A2SLC6A4 | |
| SCHEMBL2437702 | 0.80 | FNTA (0.42) | — | |
| SCHEMBL2469538 | 0.80 | FNTA (0.42) | — | |
| SCHEMBL2438996 | 0.79 | ALOX5 (0.35) | ACHEALOX5MMESLC6A2SLC6A4 | |
| SCHEMBL2442779 | 0.77 | ALOX5 (0.38) | ACHEALOX5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2439508 | 0.76 | ALOX5 (0.30) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362765-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2010065446-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-06-10 | — | — | WO | claimed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | claimed |
| EP-2362765-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2020-04-08 | — | — | EP | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431520-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20130012422-A1 | PERFUME SYSTEMS | SMETS JOHAN (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137178-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012422-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | XDH 1020/4885ACHE 69/4885ALOX5 191/4885 |
| US-20100137178-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | XDH 1020/4885ACHE 69/4885ALOX5 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.